Skip to main content
Prescription drug costs image by TaxRebate.org.uk via Flickr

Public Pharmaceuticals As An Antidote to Big Pharma’s Market Failure

Dana Brown

Dana Brown

Director of the Next System Project more

Health & Wellbeing

Drug-resistant “superbugs” are predicted to kill more people per year than cancer by 2050. It’s a problem that’s increasingly seen as a threat to national security, with potential consequences for trade, global development and even counterterrorism.

It’s also a problem that the pharmaceutical industry is unwilling to make the investments to address, because, they say, there is no market incentive to do so.

In an article today for The American Prospect, I argue that given this “bad case of market-incentive syndrome, it is time to consider the establishment of public pharmaceutical companies as an antidote.”

The federal government has already tried all of the traditional forms of persuasion to entice pharmaceutical companies to pour more research and development money, the article says, but the strategy has failed. The crux of the issue: “the industry’s increasingly financialized business model, which puts profits over people.”

Ensuring that the public has access to next-generation antibiotics and other life-saving drugs would require severing the tie between R&D costs and sales volume, what’s referred to in the industry as “delinkage.” “The ultimate form of delinkage would be to take the development and production of medicines like these into public hands and out of the market entirely,” I write. “What’s more, Americans across the political spectrum already support the idea of a public option in pharmaceuticals.”

You can read the full article at The American Prospect.

Dana Brown

Dana Brown

Director of the Next System Project more

More related work

Truvada pills

The US should be producing the HIV prevention drug its research helped create

We could just about end the spread of HIV if Truvada was affordable to everyone who should be taking it. This is why we need a public option to ensure broad, long-term access to essential medicines. read more
Women's March Washington 2017

A people’s state of the nation

The United States is at the very bottom in many key measures of social and economic well-being, including poverty, inequality, and longevity. No wonder Americans are frustrated and angry. read more
Elizabeth Warren against a backdrop of pills

The Warren/Schakowsky public pharma bill: a good first step

Warren and Schakowsky’s bill, by putting public manufacturing for the public good on the table as a real option, represents an important advance, but there are further important opportunities to expand the scope and impact of public pharma that we should not neglect.  read more